KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	D-1553 Sensitive: C2 – Inclusion Criteria J Thorac Oncol - 3 days (New C3) D-1553 Sensitive : C2 J Thorac Oncol - 3d	D-1553 Sensitive: C2 – Inclusion Criteria J Thorac Oncol - 3 days D-1553 Sensitive : C2 J Thorac Oncol - 3 days - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval AACR 2023 - 1 week (New C3) sotorasib Sensitive : A1 AACR 2023 - 1wk	sotorasib Sensitive: A1 - Approval AACR 2023 - 1 week sotorasib Sensitive : A1 AACR 2023 - 1 week - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	VS-6766 Sensitive: C2 – Inclusion Criteria AACR 2023 - 1 week (New D) VS-6766 Sensitive : C2 AACR 2023 - 1wk	VS-6766 Sensitive: C2 – Inclusion Criteria AACR 2023 - 1 week VS-6766 Sensitive : C2 AACR 2023 - 1 week - (New D)
KRAS G12C	Bladder Cancer	KRAS G12C	Bladder Cancer	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week (New D) adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1wk	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Bladder Cancer	KRAS G12C	Bladder Cancer	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week (New D) sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1wk	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week (New D) adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1wk	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week (New D) sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1wk	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AACR 2023 - 1 week sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	KRAS G12C inhibitor Sensitive: D – Preclinical AACR 2023 - 1 week (New D) KRAS G12C inhibitor Sensitive : D AACR 2023 - 1wk	KRAS G12C inhibitor Sensitive: D – Preclinical AACR 2023 - 1 week KRAS G12C inhibitor Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	ZG19018 + donafenib Sensitive: D – Preclinical AACR 2023 - 1 week (New D) ZG19018 + donafenib Sensitive : D AACR 2023 - 1wk	ZG19018 + donafenib Sensitive: D – Preclinical AACR 2023 - 1 week ZG19018 + donafenib Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	ZG19018 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) ZG19018 Sensitive : D AACR 2023 - 1wk	ZG19018 Sensitive: D – Preclinical AACR 2023 - 1 week ZG19018 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	ZG19018 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) ZG19018 Sensitive : D AACR 2023 - 1wk	ZG19018 Sensitive: D – Preclinical AACR 2023 - 1 week ZG19018 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	ZG19018 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) ZG19018 Sensitive : D AACR 2023 - 1wk	ZG19018 Sensitive: D – Preclinical AACR 2023 - 1 week ZG19018 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	tipifarnib Sensitive: D – Preclinical AACR 2023 - 1 week (New D) tipifarnib Sensitive : D AACR 2023 - 1wk	tipifarnib Sensitive: D – Preclinical AACR 2023 - 1 week tipifarnib Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VIC-1911 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) sotorasib + VIC-1911 Sensitive : D AACR 2023 - 1wk	sotorasib + VIC-1911 Sensitive: D – Preclinical AACR 2023 - 1 week sotorasib + VIC-1911 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib + JSI-1187 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) sotorasib + JSI-1187 Sensitive : D AACR 2023 - 1wk	sotorasib + JSI-1187 Sensitive: D – Preclinical AACR 2023 - 1 week sotorasib + JSI-1187 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	TEB-17231 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) TEB-17231 Sensitive : D AACR 2023 - 1wk	TEB-17231 Sensitive: D – Preclinical AACR 2023 - 1 week TEB-17231 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + adagrasib Sensitive: B - Late Trials cetuximab + adagrasib Sensitive : B	cetuximab + adagrasib Sensitive: B - Late Trials cetuximab + adagrasib Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + BBP-398 Sensitive: B - Late Trials sotorasib + BBP-398 Sensitive : B	sotorasib + BBP-398 Sensitive: B - Late Trials sotorasib + BBP-398 Sensitive : B
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Cholangiocarcinoma	KRAS G12C	Cholangiocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Ovarian Cancer	KRAS G12C	Ovarian Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Melanoma	KRAS G12C	Melanoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Pancreatic Ductal Adenocarcinoma	KRAS G12C	Pancreatic Ductal Adenocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RMC-4630 Sensitive: C2 – Inclusion Criteria RMC-4630 Sensitive : C2	RMC-4630 Sensitive: C2 – Inclusion Criteria RMC-4630 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2

KRAS G12C

Associations